Accendra Health opened lower at $0.23, compared with its previous close of $0.23. In the last trading session, the stock traded between $0.23 and $0.24. It showed a sideways intraday trend.
An investment of $100 made 1 year ago in Accendra Health is now worth
$ 10.04
resulting in a loss of
$ 89.96 (89.96%)
Note: Past profits do not guarantee future returns.
Rating from 5 Analysts
Today's Change
+$0.00 (+0.00%)
Day High
$0.24
Day Low
$0.23
Day Open
$0.23
Prev Close
$0.23
Volume
5,01,450
1W Return
9.91%
1M Return
-63.25%
3M Return
-92.99%
6M Return
-93.32%
1Y Return
-89.96%
Market Cap ($ Mn)
18
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
0.26%
EPS (TTM)
$-1.16
1 Week
9.91%
1 Month
-63.25%
3 Months
-92.99%
6 Months
-93.32%
9 Months
-88.80%
Accendra Health gets NYSE notice over sub-$1 share price
Accendra Health received an NYSE notice on October 6, 2026, for failing to maintain a $1.00 average share price. The company has a six-month cure period to regain compliance without immediate delisting. Management is considering a reverse stock split, subject to shareholder approval by May 2027. Trading continues on the NYSE during the cure period, unaffected by the notice.
20 days agoAccendra Health names Gardner-Smith CEO, Lloyd CCO effective Oct 5
Accendra Health names Kenneth Gardner-Smith next President and CEO. Gardner-Smith assumes role early Q4 2026, succeeding Edward A. Pesicka. Scott Lloyd appointed Chief Commercial Officer effective October 5, 2026. New CCO role centralizes commercial strategy and sales leadership.
1mo agoAccendra Health drops ATM plan, targets mid-2026 for CEO successor
Accendra Health cancels its planned ATM equity issuance program due to unfavorable market conditions, stating it will not impact operations or guidance. The company remains confident in its liquidity, backed by a $300 million undrawn credit facility and $45 million in expected proceeds from non-core asset sales. Additionally, the Board expects to announce a CEO successor by mid-September 2026, ensuring a smooth transition before Mr. Pesicka's planned retirement at year-end.
2mo agoAccendra Health adopts tax asset plan to shield NOLs
Accendra Health implements a Tax Asset Preservation Plan to protect net operating loss carryforwards under Section 382 of the Internal Revenue Code. The plan deters acquisitions exceeding 4.9% ownership by offering discounted shares to non-triggering holders, remaining effective until August 2029.
2mo agoAccendra Health CEO Edward Pesicka plans retirement by 2026
Edward A. Pesicka, President and CEO of Accendra Health, Inc., plans to retire by the end of 2026 after over seven years with the company. The Board will use its pre-established succession plan to select his successor, with Mr. Pesicka potentially serving in an advisory role to ensure a smooth transition.
2mo agoAccendra Health files prospectus for $200M mixed shelf
Accendra Health filed a prospectus for a $200M mixed shelf offering with the SEC. The offering includes debt securities, common stock, preferred stock, and warrants. Proceeds are intended for general corporate purposes.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $980.88 | +2.12% | $1,14,360.80M | 23.95 | |
| $330.53 | +1.91% | $63,074.05M | 23.91 | |
| $251.09 | +2.59% | $58,142.15M | 32.44 | |
| $86.44 | +1.74% | $9,633.48M | 26.11 | |
| $1.33 | +2.31% | $1,135.88M | - | |
| $4.17 | -2.11% | $156.49M | - | |
| $0.28 | +11.45% | $27.93M | - | |
| $2.98 | +0.34% | $15.10M | - | |
| $2.03 | -7.73% | $9.17M | - | |
| $2.19 | +0.46% | $4.62M | - |
An investment of $100 made 1 year ago in Accendra Health is now worth
$ 10.04
resulting in a loss of
$ 89.96 (89.96%)
Note: Past profits do not guarantee future returns.
